LSE:GSK 31 January 2026

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent surged Tuesday after GSK said it would buy the Nasdaq-listed biotech for $10.6 billion, or $124 a share in cash. The stock shot up 38.9% to $122.93, almost reaching the offer price and trading like the day’s standard merger-arb play.

9 June 2026

Biotechnology·LSE:GSK·NASDAQ:NUVA·Stock Market

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK is set to acquire U.S.-based Nuvalent for $10.6 billion in cash, making it the largest deal GSK has made in years. The offer is $124 per share, which works out to a 40% premium on Nuvalent’s previous closing price. It’s an early move by CEO Luke Miels as he looks to revamp the British group’s oncology pipeline.

9 June 2026

LSE:GSK·NASDAQ:NUVL·Pharmaceuticals

FTSE 100 Falls Today as AstraZeneca and GSK Drag London Stocks Lower

London’s FTSE 100 slipped 0.6% to 10,270.96 as of 10:39 BST, while the FTSE 250 hovered, edging down just 0.05% to 22,389.12.

29 April 2026

FTSE 100·LSE:AZN·LSE:GSK·Stock Market

GSK steps up share buyback as fresh annual report spells out CEO Luke Miels’ 2026 priorities

GSK picked up 650,000 shares on Thursday for its buyback, paying prices from 2,072 pence up to 2,135 pence apiece. Those shares are headed for treasury, according to the company.

6 March 2026

LSE:GSK·Pharmaceuticals·Stock Market

GSK share price today: stock edges up after $2.2 billion RAPT deal closes and buyback rolls on

GSK edged up 0.8% to 2,138 pence as of 0947 GMT on Wednesday, clawing back some losses from the previous session, after the company said it wrapped up its acquisition of RAPT Therapeutics. The most recent closing price, according to delayed data, was 2,122 pence.

4 March 2026

LSE:GSK·Pharmaceuticals·Stock Market

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

GSK plc shares edged higher Friday morning, gaining 0.74% to 2,183 pence by 0855 GMT, as investors parsed several pipeline updates from the last 48 hours.

27 February 2026

LSE:GSK·Pharmaceuticals·Stock Market

GSK shares nudge up on $950 mln 35Pharma deal as dealmaking picks up

GSK ticked up Wednesday, following its $950 million cash deal to acquire Canada’s 35Pharma and take on an in-development pulmonary hypertension therapy.

25 February 2026

LSE:GSK·Pharmaceuticals

GSK stock price today: shares tick up as buyback rolls on and Global Counsel fallout hits the tape

GSK plc shares edged up 0.4% to 2,234 pence in early London trade on Friday, after closing at 2,226 a day earlier. The stock traded in a narrow range of 2,232 to 2,243 pence.

20 February 2026

LSE:GSK·Share Buybacks·Stock Market

GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK slipped 0.39% to 2,259 pence by 0901 GMT in early London trading, following new real-world data on its RSV shot Arexvy and the stock going ex-dividend. The shares had kicked off at 2,252 pence, just a day after touching a 52-week peak of 2,282 pence; they’ve climbed roughly 57% in the last year.

19 February 2026

Dividends·Earnings Reports·LSE:GSK·Pharmaceuticals·Stock Market

GSK share price in focus: £450 million buyback tranche starts as London trading nears

GSK caught attention ahead of Tuesday’s London session, with the drugmaker announcing the launch of a fresh £450 million piece of its share buyback program.

17 February 2026

LSE:GSK·Share Buybacks·Stock Market

GSK share price hovers near a 52-week high as COPD approval, U.S. drug discounts come into view

GSK edged up roughly 0.6% in early Monday action in London, with the stock hovering close to its 52-week peak. Shares hit 2,214 pence before settling at 2,211 by 0812 GMT.

9 February 2026

LSE:GSK·Pharmaceuticals·Stock Market

GSK share price dips at London open after 52-week high — what investors watch next

GSK plc shares edged down 0.8%, hitting 2,162 pence in early London trading Friday, after an opening at 2,166 pence. The stock fluctuated between 2,162 and 2,169 pence, hovering near its 52-week peak of 2,196.

6 February 2026

LSE:GSK·Stock Market

FTSE 100 slips from highs as Bank of England looms; Shell results hit UK shares today

UK stocks eased on Thursday, with the FTSE 100 down about 0.2% at 10,382 points by 1052 GMT, as traders trimmed positions ahead of central bank news and a busy earnings tape.

5 February 2026

Bank of England·FTSE 100·LSE:BEZ·LSE:GSK·LSE:RDSA·Stock Market·SWX:ZURN·UK Economy

GSK stock leaps to a 25-year high on new CEO outlook — what to watch at the London open

GSK plc shares look to extend a strong bounce when London markets open Thursday, after closing Wednesday at 2,080 pence—a 6.9% gain—with intraday highs reaching 2,111 pence. In New York, GSK’s ADRs climbed to $57.23, up $3.89 in late trade.

5 February 2026

LSE:GSK·NYSE:GSK·Stock Market

FTSE 100 breaks 10,400 as Zurich-Beazley bid and GSK lift UK stocks ahead of BoE

London's main index climbed on Wednesday, the FTSE 100 rising 1.0% to 10,418.51 by 10:40 GMT, having briefly hit 10,419.51 earlier in the session. The mid-cap FTSE 250 added 0.4%, reaching 23,392.40.

4 February 2026

FTSE 100·LSE:BEZ·LSE:GSK·Stock Market·SWX:ZURN·UK Economy

GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

GSK shares recovered on Wednesday following the release of new CEO Luke Miels’ first sales forecast, which showed slower growth for 2026—a key test investors had been eyeing. After an early dip of roughly 1%, the stock climbed 1.4% by 0809 GMT.

4 February 2026

Earnings Reports·LSE:GSK·Pharmaceuticals·Stock Market

GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool

GSK is projecting slower sales growth in 2026 under new CEO Luke Miels, who took over from Emma Walmsley earlier this year. The company is bracing for patent expiries on its leading HIV drugs starting in 2028. It now expects revenue growth of 3% to 5% at constant currency, while warning that vaccines and general medicines sales might decline. Shares climbed 1.4% by 0809 GMT after an initial drop. Core earnings per share for Q4 came in at 25.5 pence, supported by an 8% sales increase to £8.62 billion.

4 February 2026

LSE:GSK·Pharmaceuticals

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK shares nudged higher in early trading Tuesday, hovering close to a one-year peak ahead of the British drugmaker’s earnings report. The stock gained 0.1% to 1,926.5 pence, after touching 1,928.5 pence earlier.

3 February 2026

Earnings Reports·LSE:GSK·NASDAQ:WVE·Pharmaceuticals·Stock Market

GSK share price rises into earnings week — what traders watch before Feb 4 results

GSK shares closed Friday 1.32% higher at 1,876.50 pence, marking a steadier start to the month following a volatile January. As London markets remained closed over the weekend, focus now turns to upcoming earnings reports and the tone set by management.

1 February 2026

Earnings Reports·LSE:GSK·Stock Market

GSK stock price ends week higher as Feb 4 earnings loom — what investors watch next

GSK shares gained 1.32% on Friday, closing at 1,876.5 pence. The stock outperformed a stronger FTSE 100 but still remains roughly 9% shy of its 52-week peak from December.

31 January 2026

Earnings Reports·LSE:GSK·Stock Market

LSE:GSK 31 January 2026 - 9 June 2026